Abstract
This chapter is a compilation of a few uncommon, hyperpigmented enigmatic dermatoses of unclear etiology that are difficult to diagnose and treat. They include lichen planus pigmentosus, erythema dyschromicum perstans, ashy dermatosis, idiopathic eruptive macular pigmentation, and acquired brachial cutaneous dyschromatosis. Most of them are more prevalent in Latin America or India as they usually involve patients with Fitzpatrick skin type IV and V. These dermatoses when present in dark-skinned population have a tremendous psychological impact and are often a sociocultural setback for the patients because pigmentary dermatoses are a bane of the colored population. As a result, they desperately seek treatment ranging from self-treatment with steroid-containing creams to home remedies to treatments offered by general practitioners, many of whom are not even qualified to treat. The financial impact of these treatments is significant as well as the impact on the quality of life due to the chronic nature of these diseases. Also, many of these conditions are mired in taxonomical confusion due to their similarity on several counts.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bhutani LK, Bedi TR, Pandhi RK, Nayak NC. Lichen planus pigmentosus. Dermatologica. 1974;149(1):43–50. https://doi.org/10.1159/000251470. PMID: 4154221.
Kanwar AJ, Dogra S, Handa S, Parsad D, Radotra BD. A study of 124 Indian patients with lichen planus pigmentosus. Clin Exp Dermatol. 2003;28(5):481–5. https://doi.org/10.1046/j.1365-2230.2003.01367.x. PMID: 12950331.
Robles-Méndez JC, Rizo-FrÃas P, Herz-Ruelas ME, Pandya AG, Ocampo CJ. Lichen planus pigmentosus and its variants: review and update. Int J Dermatol. 2018;57(5):505–14.
Kumarasinghe SPW, Pandya A, Chandran V, Rodrigues M, Dlova NC, Kang HY, Ramam M, Dayrit JF, Goh BK, Parsad D. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. Int J Dermatol. 2019;58(3):263–72.
Mendiratta V, Sanke S, Chander R. Lichen planus Pigmentosus: a Clinico-etiological study. Indian Dermatol Online J. 2019;10(3):288–92.
Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol. 2010;24(5):535–40. https://doi.org/10.1111/j.1468-3083.2009.03460.x. Epub 2009 Oct 15. PMID: 19840200.
Pirmez R, Duque-Estrada B, Donati A, Campos-do-Carmo G, Valente NS, Romiti R, Sodré CT, Tosti A. Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia. Br J Dermatol. 2016;175(6):1387–90. https://doi.org/10.1111/bjd.14722. Epub 2016 Oct 23. PMID: 27233640.
Kim JE, Won CH, Chang S, et al. Linear lichen planus pigmentosus of the forehead treated by neodymium: yttrium aluminum- garnet laser and topical tacrolimus. J Dermatol. 2012;39:189–91.
Sindhura KB, Vinay K, Kumaran MS, et al. Lichen planus pigmentosus: a retrospective clinico-epidemiologic study with emphasis on the rare follicular variant. J Eur Acad Dermatol Venereol. 2015;30:e142–4.
Verma P, Pandhi D. Topical tacrolimus and oral dapsone combination regimen in lichen planus pigmentosus. Skinmed. 2015;13:351–4.
Muthu SK, Narang T, Saikia UN, et al. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55:1048–54.
Vinay K, Kumar S, Bishnoi A, Aggarwal D, Radotra BD, Parsad D, Sendhil KM. A clinico-demographic study of 344 patients with lichen planus pigmentosus seen in a tertiary care center in India over an 8-year period. Int J Dermatol. 2020;59(2):245–52. https://doi.org/10.1111/ijd.14540. Epub 2019 Jun 23. PMID: 31231800.
Ramirez CO. The ashy dermatosis (erythema dyschromicum perstans). Epidemiological study and report of 139 cases. Cutis. 1967;3:244–7.
Convit J, Kerdel-Vegas F, Rodriguez G. Erythema dyschromicum perstans. A hitherto undescribed skin disease. J Invest Dermatol. 1961;36:457–65.
Torrelo A, Zaballos P, Colmenero I, et al. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol. 2005;19:422–6.
Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–8.
Udompanich S, Vachiramon V. Acquired macular pigmentation of unknown etiology. J Clin Aesthet Dermatol. 2019;12(1):38–46. Epub 2019 Jan 1. PMID: 30881577; PMCID: PMC6405250.
Imanishi H, Tsuruta D, Kobayashi H, et al. Two cases of unilateral ashy dermatosis. Case Rep Dermatol. 2011;3:1–4. 38
Chang SE, Kim HW, Shin JM, Lee JH, Na JI, Roh MR, Lee JH, Lee GY, Ko JY. Clinical and histological aspect of erythema dyschromicum perstans in Korea: a review of 68 cases. J Dermatol. 2015;42(11):1053–7. https://doi.org/10.1111/1346-8138.13002. Epub 2015 Jun 29. PMID: 26118942.
Kontochristopoulos GJ, Aroni K, Anagnostopoulos G, et al. Erythema dyschromicum perstans and hepatitis C virus infection. Int J Dermatol. 2001;40:346–8.
Melo CRF, Sa MC, Carvalho S. Erythema dyschromicum perstans in a child following an enteroviral meningitis. An Bras Dermatol. 2017;92:137–8.
Venencie PY, Lemay D, Verroust F. Erythema dyschromicum perstans following human immunodeficiency virus seroconversion in a child with hemophilia B. Arch Dermatol. 1988;124:1013–4.
Correa MC, Memije EV, Vargas-Alarcon G, et al. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican mestizo patients. J Am Acad Dermatol. 2007;56:617–20.
Vasquez-Ochoa LA, Isaza-Guzman DM, Orozco-Mora B, et al. Immunopathologic study of erythema dyschromicum perstans (ashy dermatosis). Int J Dermatol. 2006;45:937–41.
Li S, Arvisais-Anhalt S, Vandergriff T, Le LQ. Ashy dermatosis-like hyperpigmentation in a patient taking hydroxyurea. JAAD Case Rep. 2020;6(9):797–800. https://doi.org/10.1016/j.jdcr.2020.06.030. PMID: 32875022; PMCID: PMC7452229.
Tienthavorn T, Tresukosol P, Sudtikoonaseth P. Patch testing and histopathology in Thai patients with hyperpigmentation due to erythema dyschromicum perstans, lichen planus pigmentosus, and pigmented contact dermatitis. Asian Pac J Allergy Immunol. 2014;32:185–92.
Mahajan VK, Chauhan PS, Mehta KS, et al. Erythema dyschromicum perstans: response to topical tacrolimus. Indian J Dermatol. 2015;60:525.
Bahadir S, Cobanoglu U, Cimsit G, et al. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol. 2004;43:220–2.
Wang F, Zhao YK, Wang Z, et al. Erythema dyschromicum perstans: response to isotretinoin. JAMA Dermatol. 2016;152:841–2.
Degos R, Civatte J, Belaich S. La pigmentation maculeuse eruptive idiopathique. Ann Dermatol Venereol. 1978;105:177–82.
Sanz de Galdeano C, Leaute-Labreze C, Bioulac-Sage P, et al. Idiopathic eruptive macular pigmentation: report of 5 patients. Pediatr Dermatol. 1996;13:274–7.
Joshi R, Palwade PK. Idiopathic eruptive macular pigmentation or acanthosis nigricans? Indian J Dermatol Venereol Leprol. 2010;76:591.
Rongioletti F, Rebora A. Acquired brachial cutaneous dyschromatosis: a common pigmentary disorder of the arm in middle-aged women. J Am Acad Dermatol. 2000;42:680–4.
Hu SW, Chu J, Meehan S, Kamino H, et al. Acquired brachial cutaneous dyschromatosis. Dermatol Online J. 2011;17:16.
Abidi N, Foering K, Sahu J. Acquired brachial cutaneous dyschromatosis in a 60-year-old male: a case report and review of the literature. Case Rep Dermatol Med. 2014;2014:452720.
Choi MJ, Byun JY, Choi HY, et al. Acquired brachial cutaneous Dyschromatosis in a middle aged Malle. Ann Dermatol. 2018;30(3):342–4.
Ritter CG, Fiss DVC, da Borges Costa JAT, et al. Extra-facial melasma: clinical, histopathological, and Immunohistochemical Case-Control Study. J Eur Acad Dermatol Venereol. 2013;27(9):1088–94.
O’brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Austr J Dermatol. 1997;38:35–7.
Park JH, Lee DJ, Lee YJ, et al. Acquired bilateral telangiectatic macules: a distinct clinical entity. JAMA Dermatol. 2014;150:974–7.
Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2:253–62.
Hayashi M, Suzuki T. Dyschromatosis symmetrica hereditaria. J Dermatol. 2013;40(5):336–43.
Picardo M, Carrera M. New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin. 2007;25(3):353–ix. https://doi.org/10.1016/j.det.2007.04.012.
Tierney EP, Hanke CW. Review of the literature: treatment of dyspigmentation with fractionated resurfacing. Dermatol Surg. 2010;36(10):1499–508.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Poojary, S., Rongioletti, F. (2021). Acquired Hyperpigmentation Disorders of Uncertain Etiology. In: Rongioletti, F., Smoller, B.R. (eds) New and Emerging Entities in Dermatology and Dermatopathology. Springer, Cham. https://doi.org/10.1007/978-3-030-80027-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-80027-7_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80026-0
Online ISBN: 978-3-030-80027-7
eBook Packages: MedicineMedicine (R0)